Allakos Inc. SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of ...

Overview: Allakos Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting immunomodulatory receptors on immune effector cells for allergy, inflammatory ...

Allakos (ALLK) has entered into a definitive merger agreement whereby Concentra Biosciences will acquire Allakos for $0.33 in cash per share of Allakos common stock. Allakos’ Board of Directors ...

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra.

(MENAFN- GlobeNewsWire - Nasdaq) SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has ...

Allakos’ Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos’ ...

SAN CARLOS, Calif. - Allakos Inc. (NASDAQ:ALLK), a biotechnology firm focused on developing antibodies to treat allergic and inflammatory diseases, has announced a definitive merger agreement with ...

Morningstar brands and products Company Portfolio ...

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and ...

SAN CARLOS, Calif. - Allakos Inc. (NASDAQ:ALLK), a biotechnology firm focused on developing antibodies to treat allergic and inflammatory diseases, has announced a definitive merger agreement with ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses, struggling Allakos is welcoming a $0.33 per share buyout offer wi ...